Market For Cardiac Devices Set to Increase to $11.8 Billion By 2001, Says Clinica's Latest Cardiovascular Report
RICHMOND, UK, June 22 /PRNewswire/ -- The CVD market is still proving to be an attractive market for new
entrants. Developments in less invasive surgery techniques and devices, plus a global increase in the occurrence of
cardiovascular disease have led to a sustained interest in the market for new products.
Cardiovascular disease is the predominant cause of premature death in the developed countries of the world. The
populations of developed nations are aging and emerging nations are embracing
Western lifestyles that will eventually lead to a massive increase in CVD in these countries -- many of these nations
already have large, wealthy middle classes readily able to afford high quality medical care.
Recent treatments for cardiovascular disease are examined in a new title from Clinica Reports. ''Clinica's Complete
Guide to Cardiovascular Devices'' includes the cardiovascular devices that are employed for the treatment of CVDs
are numerous and varied and the report focuses on those most commonly used, i.e. PTCA systems, vascular stents,
atherectomy devices, implantable pacemakers, implantable defibrillators, cardiac ablation catheters, prosthetic heart
valves, vascular grafts,
cardiovascular repair fabrics and PTA systems.
Key participants in this market that are profiled in this report are: Ave Inc., CR Bard, Baxter International, Boston
Scientific Corp [NYSE:BSX - news], Guidant, Johnson & Johnson,Medtronic, Schneider, St. Jude Medical, Sulzer
Medica, Ventritex.
Profiles include an informative company overview, details of financial performance and sales of devices by geographic
area, product descriptions and details of R&D activity.
Clinica's Complete Guide to Cardiovascular Devices Price: pounds sterling 495 / US$1,040. |
